A Pilot Study on the Effect of Cannabis Oil in Untreatable Liver Cancer Patients

Inclusion criteria

• Age =>18 yrs
• Histologically proven hepatocellular carcinoma
• Non-cirrhosis or Child Pugh A cirrhosis
• Hepatic encephalopathy grade 0 or 1
• Multidisciplinary treatment (MDT)-advised best supportive care for untreatable advanced HCC or patients unable to undergo or declining treatment for advanced HCC.
• Minimal life expectancy of 3 months
• Willing and able to attend follow-up examinations
• Willing to stop active traffic participation or controlling machinery during the study period if applicable
• Signed informed consent
• Language: Dutch or English

Exclusion criteria

• Child Pugh B or C cirrhosis
• Hepatic encephalopathy grade 2 or more
• Previous systemic treatment for HCC
• Mental conditions rendering the subject incapable to understand the nature, scope and consequences of the trial
• Use of medicinal cannabis for other purposes
• Contra-indications for medicinal cannabis oil:

• Patients who have experienced a myocardial infarction or clinically significant cardiac dysfunction within the last 12 months or have had a cardiac disorder that, in the opinion of the investigator would have put the participant at risk of a clinically significant arrhythmia or myocardial infarction.
• Patients with known psychotic disorders
• Female patients who are pregnant or lactating
• Patients (men or women) intending to start a family
• Hypersensitivity to cannabinoids or any of the excipients of the cannabis oil